Jacob leads the Global Business Development Team at Inoviv, bringing 5+ years of invaluable experience to the table. His tenure at Inoviv has been marked by pioneering efforts in implementing the use of biomarkers in clinical trials across neurodegeneration, fibrosis, oncology and others. With a background in Biochemistry from Imperial College London coupled with experience in Investment Banking/M&A at Goldman Sachs, Jacob offers a unique blend of scientific acumen and business expertise. Passionate about generating key insights to accelerate the development of new medicines, Jacob is dedicated to driving innovation and forging strategic partnerships that advance healthcare outcomes.